Action Required for Importers Impacted by COVID-19
Client Alert | 1 min read | 03.24.20
USTR Seeks Comments on Removal of Tariffs on Certain Imports from China that Assist the U.S. Coronavirus Response
The Office of the U.S. Trade Representative (USTR) is seeking comments to remove Section 301 tariffs on certain imports from China that could help support the United States COVID-19 response. The USTR recently granted approximately 200 exclusions from the tariffs on China that covered personal protective equipment products, including medical masks, examination gloves, antiseptic wipes, and other medical-care related items, as a response to the COVID-19 outbreak.
The March 20, 2020, notice is seeking comments on whether a medical-care product is “needed to respond to the COVID-19 outbreak.” The Comment window will be open until at least June 25, 2020, and may be extended.
Each comment specifically must identify the particular product of concern and explain precisely how the product relates to the response to the COVID-19 outbreak. This notice does not replace the current ongoing exclusion process. Comments may be submitted until June 25, 2020 (or until a later date if needed). However, to facilitate timely consideration, interested parties should submit comments as soon as possible.
Contacts
Insights
Client Alert | 4 min read | 01.07.26
On December 17, 2025, the U.S. Food and Drug Administration (FDA) issued a request for information (RFI) on a proposal designed to help the FDA engage more directly with innovative, venture-backed companies focused on biotechnology, medical devices, AI, and regulatory technology.[i]The RFI includes 19 questions, with responses due by 2:00 p.m. ET on January 18, 2026.
Client Alert | 3 min read | 01.07.26
CMMC for AI? Defense Policy Law Imposes AI Security Framework and Requirements on Contractors
Client Alert | 3 min read | 01.07.26
New Year, Same CIPA Uncertainty – When Will the Appellate Courts Enter the Chat?
Client Alert | 11 min read | 01.07.26

